Related Experiment Videos
Debate: at what level of coronary heart disease risk should a statin be prescribed?
1Section of Clinical Pharmacology and Therapeutics, Royal Hallamshire Hospital, Sheffield, UK. peter.r.jackson@shef.ac.uk
Insights
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) effectively prevent coronary heart disease. Treatment benefits are greatest for individuals with higher cardiovascular risk, particularly when risk exceeds 15% for mortality benefits.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are widely used for coronary heart disease (CHD) prevention.
- Determining optimal patient selection for statin therapy remains a key clinical challenge.
Purpose of the Study:
- To evaluate the risk stratification for initiating statin treatment in primary and secondary prevention of coronary heart disease.
- To assess the benefit-risk and cost-effectiveness of statin therapy based on individual CHD risk.
Main Methods:
- Analysis of clinical trial data on statin efficacy in reducing coronary morbidity and all-cause mortality.
- Review of risk thresholds for statin initiation based on projected 10-year CHD event risk.
Main Results:
- Statin benefits are proportional to underlying CHD risk, with significant all-cause mortality reduction observed at risks of 15% or greater over 10 years.
- Cost-effectiveness is favorable at higher risk levels, justifying treatment for secondary prevention and primary prevention with risk ≥30%.
Conclusions:
- Statin therapy is most beneficial for individuals with elevated coronary heart disease risk.
- Implementation of widespread statin use is limited by cost and workload, necessitating prioritized guidelines based on risk stratification.
Abstract:
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are effective treatments for the primary and secondary prevention of coronary heart disease, but an outstanding issue is determining who should have such treatment. The benefit from treatment with statins appears to be proportional to the underlying risk of coronary heart disease and independent of the factors increasing risk. Most benefit will therefore be achieved by treating people at increased risk of coronary heart disease. Statins reduce coronary morbidity even when the risk of coronary heart disease is relatively low (6% over 10 years), but reduction in all-cause mortality, the true measure of safety has been shown only when the risk of a major coronary heart disease event is 15% over 10 years or greater. At this level of risk patients appear willing to take treatment to gain the benefit expected from statin treatment, and the cost effectiveness of statin treatment is within the range accepted for other treatments. The major impediments to the systematic introduction of statin treatment at this level of risk are the very high overall cost and the large workload in countries like Britain, where the population risk of coronary heart disease is high. For this reason, recent British guidelines correctly advise statin treatment for secondary prevention and primary prevention when the 10 year coronary heart disease risk is 30% or greater as the first priority, moving to a lower coronary heart disease threshold for primary prevention only when resources permit.